Novavax COVID-19 Vaccine Neutralizes Omicron Mutations
A new study demonstrated continuous neutralization after 3 doses.
Related Articles
Top 5 Infectious Disease News Stories: April 13-April 19
Study highlighting the first documented case of C auris moving from adult to pediatric unit in Maryland, COVID-19 physical health problems lingering 1 year after…
STI Awareness Week: An Update on Research and Clinical Management
Here is an update on the latest research and clinical management.
Trader Joe’s Salmonella Outbreak Linked to Organic Basil
Trader Joe’s pulls contaminated organic basil after multi-state illnesses were reported.
World Liver Day: An Opportunity for Education About This Vital Organ
Please join advocates for prevention to celebrate the miracles the liver performs in maintaining the bodies’ systems, and ways to increase education to the public…
Pneumonia Diagnostic Shows Limited Utility
The streptococcal pneumoniae urine antigen (SPUA) test was studied over the course of a year to determine if it provided any benefits in terms of…
A Multi-Year Analysis on Antimicrobial Use on Clostridioides difficile Infection
A study presented at the Society for Healthcare Epidemiology of America (SHEA) conference assesses the link between antibiotic use and C difficile infection in Tennessee.
Is There an Association Between Hepatitis C and Prostate Cancer?
An analysis of NHANES data found no significant association between HCV infection and risk of prostate cancer, contrary to findings from previous research.
Nigeria is the First Country to Implement the Men5CV Vaccine Recommended by WHO
Men5CV is expected to target 5 strains of the meningococcus bacteria, reducing meningitis cases across the region.
Study Reveals Transmission of Candida auris from Adults to Children in Maryland Hospital
The results were presented at the Society for Healthcare Epidemiology of America (SHEA) conference, highlighting this first documented case of C auris moving from an…
GSK 5-in-1 Meningococcal Vaccine Given a PDUFA
The company’s investigational ABCWY vaccine candidate will be reviewed by the FDA by February 14, 2025.